Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time

Denton, Texas, December 13, 2021/PRNewswire/ - HealthTrackRx, a leading polymerase chain reaction (PCR) testing laboratory, today confirmed that it has been approved by the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to perform Molecular Laboratory Development (LDT) COVID-19 authorization testing. The laboratory is one of only 27 laboratories in the country that allows the use of LDT COVID-19 testing under the FDA EUA.

“Since the beginning of the pandemic, HealthTrackRx has made significant progress in making testing more accurate and accessible. We know that testing is a key tool in the fight against COVID-19, and we will continue to provide our customers with fast and accurate testing. EUA, "HealthTrackRx executive chairman Martin Price said.

EUA authority is exercised by the FDA to protect public health and safety from COVID-19 by promoting the availability and use of "Medical Measures" (MCM). The HealthTrackRx real-time PCR COVID-19 test is one of the best methods to accurately detect pathogens at the molecular level. Compared with culture tests, this technique can provide significantly faster results. The provider will receive COVID-19 test results within 24 hours or less.

About HealthTrackRx HealthTrackRx is the leading PCR-based infectious disease laboratory in the United States, providing clinicians across the country with industry-leading turnaround time. For more than 20 years, the company has mobilized accurate clinical decision-making through advances in pathogen detection, antimicrobial management, and value-based care programs. HealthTrackRx is one of the few laboratories in the United States that has received FDA emergency use authorization for molecular laboratory development (LDT) COVID-19 authorized testing. For more information, visit healthtrackrx.com and HealthTrackRx on LinkedIn.

More news releases on similar topics

Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time